

Luana Benedetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6960564/publications.pdf>

Version: 2024-02-01

84
papers

4,110
citations

159525

30
h-index

118793

62
g-index

86
all docs

86
docs citations

86
times ranked

4157
citing authors

#	ARTICLE	IF	CITATIONS
1	The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. <i>Lancet, The</i> , 2012, 379, 2352-2363.	6.3	1,018
2	Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. <i>Lancet Neurology, The</i> , 2008, 7, 136-144.	4.9	582
3	Regional variation of Guillain-Barré syndrome. <i>Brain</i> , 2018, 141, 2866-2877.	3.7	190
4	Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. <i>Lancet Neurology, The</i> , 2009, 8, 158-164.	4.9	155
5	A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. <i>European Journal of Neurology</i> , 2010, 17, 289-294.	1.7	115
6	Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 125-132.	0.9	108
7	Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 306-308.	0.9	106
8	Timing and Course of Clinical Response to Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. <i>Archives of Neurology</i> , 2010, 67, 802.	4.9	99
9	Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. <i>Journal of the Peripheral Nervous System</i> , 2007, 12, 102-107.	1.4	98
10	International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome. <i>Journal of the Peripheral Nervous System</i> , 2017, 22, 68-76.	1.4	89
11	LONG-TERM EFFECT OF RITUXIMAB IN ANTI-MAG POLYNEUROPATHY. <i>Neurology</i> , 2008, 71, 1742-1744.	1.5	75
12	Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. <i>European Journal of Neurology</i> , 2011, 18, 1417-1421.	1.7	71
13	Health-related quality-of-life improvements in CIDP with immune globulin IV 10%. <i>Neurology</i> , 2009, 72, 1337-1344.	1.5	57
14	Electrophysiologic correlations with clinical outcomes in CIDP. <i>Muscle and Nerve</i> , 2010, 42, 492-497.	1.0	56
15	Reliability of clinical outcome measures in Charcot-Marie-Tooth disease. <i>Neuromuscular Disorders</i> , 2008, 18, 19-26.	0.3	55
16	Mycophenolate mofetil in dysimmune neuropathies: A preliminary study. <i>Muscle and Nerve</i> , 2004, 29, 748-749.	1.0	51
17	Validation of the Italian version of the Neuropathic Pain Symptom Inventory in peripheral nervous system diseases. <i>Neurological Sciences</i> , 2009, 30, 99-106.	0.9	51
18	Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15. <i>Journal of Neuroinflammation</i> , 2017, 14, 224.	3.1	50

#	ARTICLE	IF	CITATIONS
19	A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): The study protocol [EudraCT no.: 2006-000032-27]. <i>Pharmacological Research</i> , 2006, 54, 436-441.	3.1	47
20	Cell-based assays for the detection of MOG antibodies: a comparative study. <i>Journal of Neurology</i> , 2020, 267, 3555-3564.	1.8	44
21	Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV. <i>Muscle and Nerve</i> , 2009, 39, 448-455.	1.0	42
22	Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited. <i>Trials</i> , 2011, 12, 252.	0.7	38
23	Variables influencing quality of life and disability in Charcot Marie Tooth (CMT) patients: Italian multicentre study. <i>Neurological Sciences</i> , 2006, 27, 417-423.	0.9	37
24	Consistence and discrepancy of neuropathic pain screening tools DN4 and ID-Pain. <i>Neurological Sciences</i> , 2013, 34, 373-377.	0.9	36
25	Impairment of PMP22 transgenic Schwann cells differentiation in culture: implications for Charcot-Marie-Tooth type 1A disease. <i>Neurobiology of Disease</i> , 2004, 16, 263-273.	2.1	34
26	Quality of life and disability assessment in neuropathy: a multicentre study. <i>Journal of the Peripheral Nervous System</i> , 2005, 10, 3-10.	1.4	34
27	Does parkin play a role in the peripheral nervous system? A family report. <i>Movement Disorders</i> , 2004, 19, 978-981.	2.2	33
28	Safety and Tolerability of Immune Globulin Intravenous in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. <i>Archives of Neurology</i> , 2010, 67, 1082.	4.9	33
29	Charcot-Marie-Tooth and pain: correlations with neurophysiological, clinical, and disability findings. <i>Neurological Sciences</i> , 2008, 29, 193-194.	0.9	32
30	Ramsay-Hunt syndrome complicated by unilateral multiple cranial nerve palsies. <i>Neurological Sciences</i> , 2008, 29, 497-498.	0.9	31
31	Relapses After Treatment With Rituximab in a Patient With Multiple Sclerosis and Anti-Myelin-Associated Glycoprotein Polyneuropathy. <i>Archives of Neurology</i> , 2007, 64, 1531.	4.9	30
32	Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura. <i>Muscle and Nerve</i> , 2008, 38, 1076-1077.	1.0	29
33	Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study. <i>European Journal of Neurology</i> , 2020, 27, 633-643.	1.7	29
34	IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 1094-1097.	0.9	28
35	Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP Database. <i>European Journal of Neurology</i> , 2020, 27, 136-143.	1.7	27
36	Clinical epidemiology of ALS in Liguria, Italy. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 52-57.	1.1	26

#	ARTICLE	IF	CITATIONS
37	Tocilizumab in MOG-antibody spectrum disorder: a case report. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 312-314.	0.9	24
38	COVID-19-related and not related Guillain-Barré syndromes share the same management pitfalls during lock down: The experience of Liguria region in Italy. <i>Journal of the Neurological Sciences</i> , 2020, 418, 117114.	0.3	24
39	Estimating the impact of COVID-19 pandemic on services provided by Italian Neuromuscular Centers: an Italian Association of Myology survey of the acute phase. <i>Acta Myologica</i> , 2020, 39, 57-66.	1.5	24
40	Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101430.	0.9	23
41	Relationship between clinical examination, Quality of Life, disability and depression in CMT patients: Italian Multicenter study. <i>Neurological Sciences</i> , 2008, 29, 157-162.	0.9	22
42	Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1092-1099.	0.9	22
43	CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 303-310.	0.9	20
44	Uveitis as a Presenting Sign of Giant Cell Arteritis. <i>Journal of Neuro-Ophthalmology</i> , 2005, 25, 247-248.	0.4	19
45	Early abnormalities in sciatic nerve function and structure in a rat model of Charcot-Marie-Tooth type 1A disease. <i>Experimental Neurology</i> , 2004, 190, 213-223.	2.0	18
46	Importance of intensive and prolonged rehabilitative treatment on the Guillain-Barré syndrome long-term outcome: a retrospective study. <i>Neurological Sciences</i> , 2020, 41, 321-327.	0.9	18
47	The spectrum of GNE mutations: allelic heterogeneity for a common phenotype. <i>Neurological Sciences</i> , 2010, 31, 377-380.	0.9	17
48	B-cell-activating factor in rituximab-treated patients with anti-MAG polyneuropathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1291-1294.	0.9	17
49	Relevance of diagnostic investigations in chronic inflammatory demyelinating polyradiculoneuropathy: Data from the Italian CIDP database. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 152-161.	1.4	15
50	Chronic inflammatory demyelinating polyradiculoneuropathy: can a diagnosis be made in patients not fulfilling electrodiagnostic criteria?. <i>European Journal of Neurology</i> , 2021, 28, 620-629.	1.7	15
51	Increased incidence of axonal Guillain-Barré syndrome in La Spezia area of Italy: A 13-year follow-up study. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 80-86.	1.4	14
52	Improving laboratory diagnostics in myasthenia gravis. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 579-590.	1.5	13
53	Functioning and quality of life in patients with neuropathy associated with anti-MAG antibodies. <i>Journal of Neurology</i> , 2018, 265, 2927-2933.	1.8	12
54	Molecular detection of human mammaglobin in cerebrospinal fluid from breast cancer patient with leptomeningeal carcinomatosis. <i>Journal of Neuro-Oncology</i> , 2009, 91, 295-298.	1.4	10

#	ARTICLE	IF	CITATIONS
55	Guillain-Barré syndrome following chickenpox: a case series. International Journal of Neuroscience, 2016, 126, 478-479.	0.8	10
56	Diagnostics of anti-MAG antibody polyneuropathy. Neurological Sciences, 2017, 38, 249-252.	0.9	9
57	Anti-sulfatide/galactocerebroside antibodies in immunoglobulin M paraproteinemic neuropathies. European Journal of Neurology, 2017, 24, 1334-1340.	1.7	9
58	Are basketball players more likely to develop Hirayama disease?. Journal of the Neurological Sciences, 2019, 400, 142-144.	0.3	9
59	Bendamustine+rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy. Journal of the Neurological Sciences, 2020, 413, 116777.	0.3	9
60	A diagnostic score for anti-myelin-associated glycoprotein neuropathy or chronic inflammatory demyelinating polyradiculoneuropathy in patients with anti-myelin-associated glycoprotein antibody. European Journal of Neurology, 2023, 30, 501-510.	1.7	9
61	Meningoencephalitis-like onset of post-infectious AQP4-IgG-positive optic neuritis complicated by GM1-IgG-positive acute polyneuropathy. Multiple Sclerosis Journal, 2015, 21, 246-248.	1.4	8
62	Diagnostics of dysimmune peripheral neuropathies. Neurological Sciences, 2017, 38, 243-247.	0.9	8
63	Anti-ganglioside antibodies: experience from the Italian Association of Neuroimmunology external quality assessment scheme. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1921-1925.	1.4	8
64	Could arterial spin labelling perfusion imaging uncover the invisible in methylammonium spartate receptor encephalitis?. European Journal of Neurology, 2019, 26, e86-e87.	1.7	7
65	High-dose immunoglobulin pulse therapy and risk of Covid19 infection. Journal of Neurology, 2021, 268, 1573-1575.	1.8	7
66	Subcutaneous Immunoglobulins are a Valuable Treatment Option in Myasthenia Gravis. Journal of		

#	ARTICLE	IF	CITATIONS
73	Voltage-Gated Potassium Channel Antibodies in Slow-Progression Motor Neuron Disease. <i>Neurodegenerative Diseases</i> , 2017, 17, 59-62.	0.8	3
74	Outcomes after single-cycle rituximab monotherapy in patients with anti-MAG polyneuropathy: A bi-center experience with an average follow-up of 11 years. <i>Journal of Neuroimmunology</i> , 2019, 337, 577081.	1.1	3
75	The neurophysiological lesson from the Italian CIDP database. <i>Neurological Sciences</i> , 2021, , 1.	0.9	3
76	Isolated musculocutaneous nerve involvement in COVID-19 related Neuralgic amyotrophy. Comment on: "Neuralgic amyotrophy and COVID-19 infection: 2 cases of spinal accessory nerve palsy" by Coll et al. <i>Joint Bone Spine</i> 2021;88:105196. <i>Joint Bone Spine</i> , 2021, 88, 105238.	0.8	3
77	Dysimmune mononeuropathies: A diagnosis not to be missed. <i>Muscle and Nerve</i> , 2016, 54, 1145-1146.	1.0	2
78	Late AQP4-IgG seroconversion and shrinking of brainstem MRI lesions in a patient with overlapping CIS/NMOSD. <i>Journal of Neurology</i> , 2016, 263, 2549-2551.	1.8	2
79	Patients With Suspected Severe Adverse Reactions to COVID-19 Vaccination Admitted to Intensive Care Unit: A Case Report. <i>Frontiers in Medicine</i> , 2022, 9, 823837.	1.2	2
80	N-methyl-d-aspartate receptor antibody-related pathologies and pre-existent mental state disorders. <i>Schizophrenia Research</i> , 2018, 202, 406-407.	1.1	1
81	Maintenance treatment with subcutaneous immunoglobulins in the long-term management of anti-HMCGR myopathy. <i>Neuromuscular Disorders</i> , 2021, 31, 134-138.	0.3	1
82	Prolonged distal motor latency of median nerve does not improve diagnostic accuracy for CIDP. <i>Journal of Neurology</i> , 2021, , 1.	1.8	1
83	Sacral nerve stimulation for fecal incontinence in a patient with anti-phospholipid syndrome-related autonomic neuropathy. <i>Muscle and Nerve</i> , 2016, 53, 992-994.	1.0	0
84	Dracula teeth-like image on MRI of a patient with non alcoholic Wernicke encephalopathy. <i>Journal of the Neurological Sciences</i> , 2019, 396, 121-122.	0.3	0